Proteomic annotation and identification of potential peptide vaccine of SARSomicron variant

Main Article Content

Madan Mohan
Jyothsna Gundlapally


With the incidence of COVID 19 rapid spread and huge mortality rate vaccines were developed against the primary strain of the virus. At most care and multiple measures were taken to make every individual vaccinated ad immune towards the virus. However this could not be the final solution as he virus evolved further to provide additional infections by strainĀ  variation and vaccine resistant. Several variants of Corona virus evolved which includes alpha, beta, gamma, delta and omicron all of which has a diverse pathological effects but a very high spread rate. Omicron is a new variant of corona virus that was first reported in November 2021 andis highly immunogenic. It is rapid in spreadingwhen compared to previous variants. Its incubation period is 6 days and exhibits early symptoms. omicron affects the immune system of an infected person and makes the body a hub forseveral other heart ailments. Further the current day vaccines against COVID 19 failed toprevent the infection by omicron variant, however, it is expected to minimize the pathogenicinfluence on the vaccinated host. The present research aimed to screen and compare theproteome of the Omicron variant and the wild strain of COVID, also identify the variableproteins which may be the cause of vaccine resistance. Further, a deep proteomic analysis isto be performed to identify and propose a suitable peptide vaccine against the omicron variantof SARS Coronavirus.

Article Details

How to Cite
Madan , M. M., & Gundlapally, J. . (2022). Proteomic annotation and identification of potential peptide vaccine of SARSomicron variant. Helix - The Scientific Explorer | Peer Reviewed Bimonthly International Journal, 12(3), 9-14. Retrieved from